Non-coding RNAs expression in SARS-CoV-2 infection: pathogenesis, clinical significance, and therapeutic targets

X Liu, W Xiong, M Ye, T Lu, K Yuan, S Chang… - … and Targeted Therapy, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has been looming globally for
three years, yet the diagnostic and treatment methods for COVID-19 are still undergoing …

Post-COVID-19 syndrome comprehensive assessment: from clinical diagnosis to imaging and biochemical-guided diagnosis and management

MZ Yan, M Yang, CL Lai - Viruses, 2023 - mdpi.com
The COVID-19 outbreak was first reported in 2019, causing massive morbidity and mortality.
The majority of the COVID-19 patients survived and developed Post-COVID-19 Syndrome …

Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study

H Wang, Y Wei, CT Hung, G Lin, X Jiang… - The Lancet Infectious …, 2024 - thelancet.com
Background Studies have established the short-term efficacy of nirmatrelvir–ritonavir in
managing COVID-19, yet its effect on post-COVID-19 condition, especially in patients …

Pulmonary fibrosis in patients with COVID-19: A retrospective study

F Li, J Deng, Y Song, C Wu, B Yu, G Wang… - Frontiers in Cellular …, 2022 - frontiersin.org
Background Coronavirus disease 2019 (COVID-19) pandemic has caused substantial
threats to people's physical health and lives, claiming the lives of over 6 million people …

Symptomatic post COVID patients have impaired alveolar capillary membrane function and high VE/VCO2

P Agostoni, M Mapelli, E Salvioni, I Mattavelli… - Respiratory …, 2024 - Springer
Background Post COVID-19 syndrome is characterized by several cardiorespiratory
symptoms but the origin of patients' reported symptomatology is still unclear. Methods …

[HTML][HTML] N-Acetylglucosamine mitigates lung injury and pulmonary fibrosis induced by bleomycin

J Li, X Xu, J Liu, Y Chen, S Jin, G Zhang, S Yin… - Biomedicine & …, 2023 - Elsevier
Lung injury and pulmonary fibrosis contribute to morbidity and mortality, and, in particular,
are characterized as leading cause on confirmed COVID-19 death. To date, efficient …

Determination of global chemical patterns in exhaled breath for the discrimination of lung damage in postCOVID patients using olfactory technology

BN Zamora-Mendoza, H Sandoval-Flores… - Talanta, 2023 - Elsevier
The objective of this work was to evaluate the use of an electronic nose and chemometric
analysis to discriminate global patterns of volatile organic compounds (VOCs) in breath of …

Пандемия коронавирусной болезни 2019 (COVID-19) и аутоиммунные ревматические заболевания: итоги и перспективы

ЕЛ Насонов - Научно-практическая ревматология, 2024 - rsp.mediar-press.net
Аннотация Пандемия коронавирусной болезни 2019 (COVID-19, coronavirus disease
2019), этиологически связанной с вирусом SARS-CoV-2 (severe acute respiratory …

D-dimer elevation and venous thromboembolism≥ 90 days following COVID-19: a retrospective study within a learning health system

H Naik, R Li, S Shao, K Dobosz, J Greiner… - Canadian Journal of …, 2023 - utpjournals.press
Abstract Background: In acute COVID-19, plasma D-Dimer is a useful biomarker and venous
thromboembolism (VTE) is common. However, it is less clear whether this is the case during …

Altered expression of serum lncRNA CASC2 and miRNA-21-5p in COVID-19 patients

SE Ayoub, OG Shaker, M Masoud, EA Hassan… - Human Genomics, 2024 - Springer
Infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes
coronavirus disease 2019 (COVID-19) has a high incidence of spread. On January 30 …